PreludeDx Will Present DCISionRT™ Results from SweDCIS Randomized Trial at SABCS

News provided by

Nov 30, 2017, 08:00 ET

LAGUNA HILLS, Calif., Nov. 30, 2017 /PRNewswire/ -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today that results from a clinical validation of DCISionRT^TM—The DCIS Test^TM—utilizing the SweDCIS randomized trial set will be presented at the 40^th Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, from December 5-9.

The clinical validation will be presented by Principal Investigator of SweDCIS, Fredrik Wärnberg MD PhD, Associate Professor of Surgery at Uppsala University. SweDCIS is a landmark prospective randomized clinical trial that investigated the benefit of radiation therapy in a population of over 1,000 DCIS patients with 20-year follow-up.

"We are honored that Dr. Wärnberg and his team decided to collaborate with us on a clinical validation of DCISionRT in SweDCIS. Through this collaboration, DCISionRT is the only DCIS test to be evaluated in a prospective-retrospective randomized trial that was designed to assess the test's ability to predict radiation therapy benefit," stated Daniel Forche, President and CEO of PreludeDx. He continued, "We are excited that SABCS selected a DCISionRT clinical validation as an oral presentation for the second consecutive year. It is a prestigious symposium and an excellent forum to present the latest in breast cancer innovations."

Study results will be announced in accordance with the SABCS embargo policy. Follow us on Twitter via @PreludeDx to stay up to date on news and events.

DCISionRT Oral Presentation

Title: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)
Presenter: Fredrik Wärnberg, MD, PhD
Date: Friday, December 8, 2017; 11:15AM CST
Location: GS5-08; General Session 5 – Hall 3

About DCISionRT for Breast DCIS
DCISionRT is a risk assessment test for patients with ductal carcinoma in situ (DCIS). In the US, over 60,000 women are newly diagnosed with DCIS each year. The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a woman's individual tumor biology along with other risk factors to provide a personalized recurrence risk. The test provides a Decision Score^TM that identifies a woman's risk as low or elevated. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx
PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk^TM.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: www.preludedx.com

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

SOURCE PreludeDx